DDX41 and COVID-19: However, we recently detected auto-Abs against type I IFNs in 24% (10 of 48 tested) of fully vaccinated patients with normal antibody responses who developed critical breakthrough COVID-19 (140), suggesting that at least some of the carriers of these auto-Abs may not be fully protected by the vaccine.